Immunotherapy Of Specific Bacterial Infections

There have been a number of attempts to develop type-specific antibodies for use in the treatment of staphyloccal infections (1-4). Most of them have focused on the development of vaccines to induce immunity against staphylococci (1,2) or the use of nonvirulent staphylococci to colonize individuals and prevent colonization by virulent staphylococci (3,4). None of these strategies has been shown to be effective to date, although it should be possible eventually to develop a vaccine against...

Classical And Newly Developed Vaccines

The development of inactivated vaccines resulted from the development of methods to grow microbes and to purify the toxins. The preparation of inactivated vaccines is based on a golden rule emerging from Pasteur and Ramon's studies leading to preparation of anti-rabies and toxoid vaccines, respectively a vaccine should be devoid of pathogenicity but should preserve intact its immunogenicity. Fig. 2. Intracellular mechanisms leading to generation of class I-peptide complex. Endogenous proteins...

Clinical Trials Of Dendritic Cell Immunotherapy

Numerous studies in animal models have documented that ex vivo antigen-pulsed DCs are effective inducers of pathogen-specific immunity 59,63,66,67 . However, the utility of ex vivo antigen-pulsed DCs for the prophylaxis or therapy of infection has not yet been extensively studied in humans. In the first reported DC clinical trial in HIV-infected patients, the safety and antigen-presenting properties of allogeneic or autologous DCs were investigated in seven HLA-A2 , HIV-infected patients 46 ....